Clinical and echocardiographic characteristics and B-type natriuretic peptide levels in study patients before and 30 days after TAVI
| Before TAVI | After TAVI | p Value | |
| NYHA functional class (III and IV), n (%) | 40 (90) | 7 (16) | <0.001 |
| Quality of life (MLHFQ Score) | 44±19.1 | 28±17.5 | <0.001 |
| Six-minute walk test (m) | 204±103 | 266±123 | <0.001 |
| B-type natriuretic peptide (pg/ml) | 725±837 | 423±320 | 0.005 |
| Left ventricular ejection fraction (%) | 55.8±8.5 | 58.9±8.6 | 0.013 |
| Aortic valve area (cm2) | 0.85±0.14 | 2.07±0.4 | <0.001 |
| Aortic valve peak velocity (m/s) | 4.22±0.56 | 2.04±0.35 | <0.001 |
| Aortic mean gradient (mm Hg) | 46.8±13.7 | 9.8±4 | <0.001 |
| Aortic peak gradient (mm Hg) | 72.6±19.7 | 18.1±6.6 | <0.001 |
| Aortic valve regurgitation (moderate to severe), n (%) | 10 (23) | 4 (10) | 0.142 |
| Mitral valve regurgitation (moderate to severe), n (%) | 21 (48) | 23 (52) | 0.670 |
MLHFQ, Minnesota living with heart failure questionnaire; NYHA, New York heart association.